CMN Weekly (29 October 2021) - Your Weekly CRISPR Medicine News
Some of the best links we picked up around the internet
By: Gorm Palmgren - Oct. 29, 2021
Top picks
Nanoparticle-sensitised photoporation, just or photoporation, is a promising upcoming physical transfection method for delivering macromolecules such as DNA, RNA or proteins in vitro or ex vivo. Researchers from Belgium and China now demonstrate that photothermal nanofibres can successfully deliver CRISPR–Cas9 ribonucleoprotein complexes to adherent and suspension cells. This includes embryonic stem cells and hard-to-transfect T cells without affecting cell proliferation or phenotype.
CRISPR-pioneer Virginijus Siksnys and colleagues have biochemically characterised two miniature types V-F Cas nucleases, SpCas12f1 (497 aa) and AsCas12f1 (422 aa). The findings might pave the way for the development of miniature Cas12f1-based genome editing tools.
American researchers have developed a method for effective AAV5 delivery of CRISPR/Cas9 components to the lung. The technique involved intratracheal injection and was used for editing of a lox-stop-lox-Tomato reporter in mouse lung airway. The team observed ∼19–26% Tomato-positive cells in large and small airways, including club and ciliated epithelial cell types.
An ultrasensitive method for detecting citrinin - a mycotoxin that is often found in food - has been developed by researchers in China. The technique combines double isothermal amplification with CRISPR-Cas12a and relies on antigen-modified gold nanoparticles that compete with citrinin to bind to magnetic beads coated with an anti-citrinin antibody.
Chinese researchers have used CRISPR to correct an RNA splicing defect in mice with β654-thalassemia - a prominent Chinese subtype of β-thalassemia. Gene editing was performed in mouse embryos, and 83% of live-born mice were gene-edited, 70% of which produced correctly spliced RNA.
The FDA has granted orphan drug designation to Intellia Therapeutics' NTLA-2001 to treat transthyretin (ATTR) amyloidosis. NTLA-2001 is an in vivo investigational CRISPR therapy that knocks out the transthyretin (TTR) gene and reduces the concentration of TTR protein in serum.
FDA has placed Gamida Cell's GDA-201 on hold pending modifications to donor eligibility procedures and sterility assay qualification. GDA-20 is a cryopreserved, off-the-shelf cell therapy candidate for treating patients with follicular and diffuse large B cell lymphomas. The company recently submitted an IND application to FDA for a Phase 1/2 trial with GDA-201.
A review by researchers from India focuses on the possible impact of CRISPR-Cas systems in regenerative medicines. They provide a detailed description of the CRISPR based regenerative therapeutic approaches for a horde of diseases like genetic disorders, neural diseases, and blood-related diseases is elucidated.
A paper in the Journal of Law and the Biosciences discusses the CRISPR patent rivalry and ethical licensing. The Greek authors argue that universities can emerge as important actors in the regulatory enterprise through additional ex post-licensing. They propose a market-based solution in the form of a license allowing for patent re-licensing if the licensee fails to address a predefined demand for the final product.
Huh, heh, wow
A pig kidney with a xenoantigen deletion has been transplanted into a recently deceased human with an intact circulation. The organ performed well for at least 54-hours without immediate hyperacute rejection by the recipient. Recombinetics and its regenerative medicine division, Makana Therapeutics, used gene editing to delete the alpha-Gal epitope present in the pig's kidney, which is known to be a key xenoantigen that elicits xenorejection.